NYSE:QGENLife Sciences
Is Qiagen (QGEN) A Bargain On Its Infectious Disease Testing Push?
Qiagen (QGEN) is back in focus after highlighting its molecular testing tools in the U.S. cyclosporiasis response and launching a CE-IVDR-certified bloodstream infection and antimicrobial resistance panel for its QIAstat-Dx platform in Europe.
See our latest analysis for Qiagen.
Qiagen’s recent focus on infectious disease diagnostics comes as the stock trades at US$41.37, with a 90 day share price return of 21.6% but a year to date share price return that is down 13.03%, and a 1 year total...